Prevalence and relative risk of common chronic health conditions among HSCT survivors (BMTSS), as compared with conventionally treated cancer survivors (CCSS) and sibling controls (CCSS)
| . | Relative risk grade 3-5 conditions . | Relative risk grade 3-4 conditions . | |||
|---|---|---|---|---|---|
| BMTSS (N = 145), % . | Conventionally treated, CCSS (N = 7207), % . | RR (95% CI)* . | Sibling control, CCSS (N = 4020), % . | RR (95% CI)† . | |
| Second malignant neoplasm‡ | 6.9 | 3.1 | 8.6 (2.9-25.3) | 0.6 | 14.5 (7.1-29.8) |
| Endocrine | 29.7 | 4.9 | 7.7 (4.2-14.3) | 1.3 | 29.6 (21.0-41.8) |
| Musculoskeletal | 2.1 | 0.5 | 7.4 (2.4-23.1) | 0.05 | 76.5 (11.0-531.3) |
| Gastrointestinal | 2.8 | 2.0 | 4.8 (1.0-21.7) | 0.4 | 10.4 (3.5-31.1) |
| Neurosensory impairment | 9.0 | 3.9 | 3.8 (1.4-10.3) | 1.4 | 6.6 (3.6-12.1) |
| Genitourinary | 1.4 | 0.3 | 2.9 (1.1-7.8) | 0.05 | 26.4 (3.5-196.2) |
| Cardiovascular | 4.8 | 3.2 | 0.5 (0.1-2.5) | 0.5 | 12.7 (5.4-30.0) |
| . | Relative risk grade 3-5 conditions . | Relative risk grade 3-4 conditions . | |||
|---|---|---|---|---|---|
| BMTSS (N = 145), % . | Conventionally treated, CCSS (N = 7207), % . | RR (95% CI)* . | Sibling control, CCSS (N = 4020), % . | RR (95% CI)† . | |
| Second malignant neoplasm‡ | 6.9 | 3.1 | 8.6 (2.9-25.3) | 0.6 | 14.5 (7.1-29.8) |
| Endocrine | 29.7 | 4.9 | 7.7 (4.2-14.3) | 1.3 | 29.6 (21.0-41.8) |
| Musculoskeletal | 2.1 | 0.5 | 7.4 (2.4-23.1) | 0.05 | 76.5 (11.0-531.3) |
| Gastrointestinal | 2.8 | 2.0 | 4.8 (1.0-21.7) | 0.4 | 10.4 (3.5-31.1) |
| Neurosensory impairment | 9.0 | 3.9 | 3.8 (1.4-10.3) | 1.4 | 6.6 (3.6-12.1) |
| Genitourinary | 1.4 | 0.3 | 2.9 (1.1-7.8) | 0.05 | 26.4 (3.5-196.2) |
| Cardiovascular | 4.8 | 3.2 | 0.5 (0.1-2.5) | 0.5 | 12.7 (5.4-30.0) |
BMTSS indicates Bone Marrow Transplant Survivor Study; CCSS, Childhood Cancer Survivor Study; CI, confidence interval; and RR, relative risk.
Model adjusted for age at the time of the study, sex, race or ethnicity, health insurance, treatment era, time from diagnosis, underlying diagnosis, radiation (brain, chest), and chemotherapy (anthracycline, alkylating agent, platinum agent, epidophyllotoxin).
Model adjusted for age at the time of the study, sex, and race or ethnicity.
For all groups, this category excludes basal cell and squamous cell carcinoma (grade 2). For siblings, this category includes a first cancer.